The immunopathology of cutaneous lupus erythematosus

Rheumatic Disease Clinics of North America

Volumn 40, Issue 3, 2014, Pages 455-474

  Kirchhof, Mark G ^a   Dutz, Jan P ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemokine; Cutaneous lupus erythematosus; Cytokine; Discoid lupus erythematosus; Interferon

Indexed keywords

APREMILAST; AZATHIOPRINE; BELIMUMAB; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; CLOBETASOL; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETRETIN; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; ISOTRETINOIN; LENALIDOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RETINOID; RITUXIMAB; SIFALIMUMAB; SIRUKUMAB; TACROLIMUS; TERBINAFINE; THALIDOMIDE; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; USTEKINUMAB; ALPHA INTERFERON;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; COMPLEMENT SYSTEM; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DRUG BLOOD LEVEL; DRY SKIN; EPSTEIN BARR VIRUS INFECTION; GENETIC ASSOCIATION; HEMATOLOGIC DISEASE; HORMONE SUBSTITUTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INNATE IMMUNITY; INTERFERON PRODUCTION; KERATINOCYTE; LUPUS LIKE SYNDROME; NEUROLOGIC DISEASE; NEUROTOXICITY; PANNICULITIS; PATHOGENESIS; PHOTOSENSITIVITY; PREMENOPAUSE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SMOKING; SUNLIGHT PROTECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; AUTOIMMUNITY; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; PATHOPHYSIOLOGY; RADIATION RESPONSE; RISK FACTOR;

AUTOIMMUNITY; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; ULTRAVIOLET RAYS;

EID: 84904363486     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.04.006     Document Type: Review

References (139)

1. Albrecht J., Berlin J.A., Braverman I.M., et al. Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus 2004, 13(11):839-849.
2. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277.
3. Petri M., Orbai A.M., Alarcon G.S., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64(8):2677-2686.
4. Durosaro O., Davis M.D., Reed K.B., et al. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol 2009, 145(3):249-253.
5. Gronhagen C.M., Fored C.M., Granath F., et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol 2011, 164(6):1335-1341.
6. Merola J.F., Prystowsky S.D., Iversen C., et al. Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. JAm Acad Dermatol 2013, 69(1):19-24.
7. Yao Y., Higgs B.W., Richman L., et al. Use of type I interferon-inducible mRNAs aspharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010, 12(Suppl 1):S6.
8. Sullivan K.E. Genetics of systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 2000, 26(2):229-256. v-vi.
9. Taylor K.E., Chung S.A., Graham R.R., et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet 2011, 7(2):e1001311.
10. Costa-Reis P., Sullivan K.E. Genetics and epigenetics of systemic lupus erythematosus. Curr Rheumatol Rep 2013, 15(9):369.
11. Harley I.T., Niewold T.B., Stormont R.M., et al. The role of genetic variation near interferon-kappa in systemic lupus erythematosus. JBiomed Biotechnol 2010, 2010.
12. Jarvinen T.M., Hellquist A., Koskenmies S., et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol 2010, 19(2):123-131.
13. Kuhn A., Wenzel J., Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol 2014, [Epub ahead of print].
14. Avalos-Diaz E., Alvarado-Flores E., Herrera-Esparza R. UV-A irradiation induces transcription of IL-6 and TNF alpha genes in human keratinocytes and dermal fibroblasts. Rev Rhum Engl Ed 1999, 66(1):13-19.
15. Kulms D., Poppelmann B., Yarosh D., et al. Nuclear and cell membrane effects contribute independently to the induction of apoptosis in human cells exposed to UVB radiation. Proc Natl Acad Sci USA 1999, 96(14):7974-7979.
16. Brink N., Szamel M., Young A.R., et al. Comparative quantification of IL-1beta, IL-10, IL-10r, TNF alpha and IL-7 mRNA levels in UV-irradiated human skin invivo. Inflamm Res 2000, 49(6):290-296.
17. Bashir M.M., Sharma M.R., Werth V.P. UVB and proinflammatory cytokines synergistically activate TNF-alpha production in keratinocytes through enhanced gene transcription. JInvest Dermatol 2009, 129(4):994-1001.
18. Heckmann M., Eberlein-Konig B., Wollenberg A., et al. Ultraviolet-A radiation induces adhesion molecule expression on human dermal microvascular endothelial cells. Br J Dermatol 1994, 131(3):311-318.
19. Casciola-Rosen L., Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 1997, 6(2):175-180.
20. Oke V., Vassilaki I., Espinosa A., et al. High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. JInvest Dermatol 2009, 129(8):2000-2010.
21. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupuserythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. JExp Med 1994, 179(4):1317-1330.
22. Gehrke N., Mertens C., Zillinger T., et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity 2013, 39(3):482-495.
23. Verdolini R., Bugatti L., Giangiacomi M., et al. Systemic lupus erythematosus induced by Epstein-Barr virus infection. Br J Dermatol 2002, 146(5):877-881.
24. James J.A., Kaufman K.M., Farris A.D., et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. JClin Invest 1997, 100(12):3019-3026.
25. McClain M.T., Heinlen L.D., Dennis G.J., et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005, 11(1):85-89.
26. Pender M.P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003, 24(11):584-588.
27. Zhu J. Cytomegalovirus infection induces expression of 60 KD/Ro antigen on human keratinocytes. Lupus 1995, 4(5):396-406.
28. Ho V., McLean A., Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. JClin Rheumatol 2008, 14(3):166-168.
29. Hawryluk E.B., Linskey K.R., Duncan L.M., et al. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. JCutan Pathol 2012, 39(5):481-492.
30. de Gannes G.C., Ghoreishi M., Pope J., et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143(2):223-231.
31. Lowe G., Henderson C.L., Grau R.H., et al. Asystematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011, 164(3):465-472.
32. Gronhagen C.M., Fored C.M., Linder M., et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012, 167(2):296-305.
33. Glossop J.R., Dawes P.T., Mattey D.L. Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45(10):1223-1229.
34. Dutz J., Werth V.P. Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. JInvest Dermatol 2011, 131(10):1968-1970.
35. Grimaldi C.M., Cleary J., Dagtas A.S., et al. Estrogen alters thresholds for B cell apoptosis and activation. JClin Invest 2002, 109(12):1625-1633.
36. Cutolo M., Sulli A., Capellino S., et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004, 13(9):635-638.
37. Sakabe K., Yoshida T., Furuya H., et al. Estrogenic xenobiotics increase expression of SS-A/Ro autoantigens in cultured human epidermal cells. Acta Derm Venereol 1998, 78(6):420-423.
38. Kuhn A., Herrmann M., Kleber S., et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006, 54(3):939-950.
39. Utz P.J., Hottelet M., Schur P.H., et al. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. JExp Med 1997, 185(5):843-854.
40. Janko C., Schorn C., Grossmayer G.E., et al. Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev 2008, 8(1):9-12.
41. Le Bon A., Thompson C., Kamphuis E., et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. JImmunol 2006, 176(4):2074-2078.
42. Dall'era M.C., Cardarelli P.M., Preston B.T., et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005, 64(12):1692-1697.
43. Ronnblom L., Alm G.V. Apivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. JExp Med 2001, 194(12):F59-F63.
44. Lovgren T., Eloranta M.L., Bave U., et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004, 50(6):1861-1872.
45. Farkas L., Beiske K., Lund-Johansen F., et al. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159(1):237-243.
46. Braunstein I., Klein R., Okawa J., et al. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol 2012, 166(5):971-975.
47. Wenzel J., Proelss J., Wiechert A., et al. CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. JAm Acad Dermatol 2007, 56(4):648-650.
48. Zahn S., Rehkamper C., Ferring-Schmitt S., et al. Interferon-alpha stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. Br J Dermatol 2011, 165(5):1118-1123.
49. Zahn S., Rehkamper C., Kummerer B.M., et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. JInvest Dermatol 2011, 131(1):133-140.
50. Civril F., Deimling T., de Oliveira Mann C.C., et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 2013, 498(7454):332-337.
51. Gall A., Treuting P., Elkon K.B., et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012, 36(1):120-131.
52. Robak E., Sysa-Jedrzejewska A., Dziankowska B., et al. Association of interferongamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz) 1998, 46(6):375-380.
53. Jabbari A., Suarez-Farinas M., Fuentes-Duculan J., et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. JInvest Dermatol 2014, 134(1):87-95.
54. Bashir M.M., Sharma M.R., Werth V.P. TNF-alpha production in the skin. Arch Dermatol Res 2009, 301(1):87-91.
55. Wang D., Drenker M., Eiz-Vesper B., et al. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum 2008, 58(10):3205-3215.
56. Zampieri S., Alaibac M., Iaccarino L., et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006, 65(4):545-548.
57. Werth V.P., Zhang W., Dortzbach K., et al. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. JInvest Dermatol 2000, 115(4):726-730.
58. Wetter D.A., Davis M.D. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009, 84(11):979-984.
59. Moore P.A., Belvedere O., Orr A., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285(5425):260-263.
60. Chong B.F., Tseng L.C., Kim A., et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. JDermatol Sci 2014, 73(3):216-224.
61. Groom J.R., Fletcher C.A., Walters S.N., et al. BAFF and MyD88 signals promote a lupus like disease independent of T cells. JExp Med 2007, 204(8):1959-1971.
62. Heinrich P.C., Behrmann I., Haan S., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374(Pt 1):1-20.
63. Linker-Israeli M., Deans R.J., Wallace D.J., et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. JImmunol 1991, 147(1):117-123.
64. Davas E.M., Tsirogianni A., Kappou I., et al. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999, 18(1):17-22.
65. Pflegerl P., Vesely P., Hantusch B., et al. Epidermal loss of JunB leads to a SLEphenotype due to hyper IL-6 signaling. Proc Natl Acad Sci USA 2009, 106(48):20423-20428.
66. Llorente L., Zou W., Levy Y., et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. JExp Med 1995, 181(3):839-844.
67. Ronnelid J., Tejde A., Mathsson L., et al. Immune complexes from SLE sera induceIL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis 2003, 62(1):37-42.
68. Llorente L., Richaud-Patin Y., Garcia-Padilla C., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000, 43(8):1790-1800.
69. Korn T., Bettelli E., Oukka M., et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
70. Yang J., Chu Y., Yang X., et al. Th17 and natural Treg cell population dynamics insystemic lupus erythematosus. Arthritis Rheum 2009, 60(5):1472-1483.
71. Tanasescu C., Balanescu E., Balanescu P., et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med 2010, 21(3):202-207.
72. Meller S., Winterberg F., Gilliet M., et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005, 52(5):1504-1516.
73. Wenzel J., Worenkamper E., Freutel S., et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. JPathol 2005, 205(4):435-442.
74. Flier J., Boorsma D.M., van Beek P.J., et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. JPathol 2001, 194(4):398-405.
75. Wenzel J., Zahn S., Mikus S., et al. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol 2007, 157(4):752-757.
76. Franz B., Fritzsching B., Riehl A., et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007, 56(6):1910-1920.
77. Jacobi A.M., Zhang J., Mackay M., et al. Phenotypic characterization of autoreactive B cells-checkpoints of B cell tolerance in patients with systemic lupus erythematosus. PLoS One 2009, 4(6):e5776.
78. Blair P.A., Norena L.Y., Flores-Borja F., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32(1):129-140.
79. Magro C.M., Segal J.P., Crowson A.N., et al. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. JCutan Pathol 2010, 37(6):659-671.
80. Lin J.H., Dutz J.P., Sontheimer R.D., et al. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol 2007, 33(1-2):85-106.
81. Sontheimer R.D., Maddison P.J., Reichlin M., et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982, 97(5):664-671.
82. Truedsson L., Bengtsson A.A., Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007, 40(8):560-566.
83. Korb L.C., Ahearn J.M. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. JImmunol 1997, 158(10):4525-4528.
84. Lood C., Gullstrand B., Truedsson L., et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum 2009, 60(10):3081-3090.
85. Gaipl U.S., Munoz L.E., Grossmayer G., et al. Clearance deficiency and systemic lupus erythematosus (SLE). JAutoimmun 2007, 28(2-3):114-121.
86. Teichmann L.L., Ols M.L., Kashgarian M., et al. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010, 33(6):967-978.
87. Hansel A., Gunther C., Baran W., et al. Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. JAutoimmun 2013, 40:1-8.
88. Mendez-Reguera A., Perez-Montesinos G., Alcantara-Hernandez M., et al. Pathogenic CCR6+ dendritic cells in the skin lesions of discoid lupus patients: a role for damage-associated molecular patterns. Eur J Dermatol 2013, 23(2):169-182.
89. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303(5663):1532-1535.
90. Leffler J., Gullstrand B., Jonsen A., et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther 2013, 15(4):R84.
91. Garcia-Romo G.S., Caielli S., Vega B., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3(73):73ra20.
92. Guiducci C., Tripodo C., Gong M., et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. JExp Med 2010, 207(13):2931-2942.
93. Villanueva E., Yalavarthi S., Berthier C.C., et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. JImmunol 2011, 187(1):538-552.
94. Barrat F.J., Meeker T., Gregorio J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. JExp Med 2005, 202(8):1131-1139.
95. Barrat F.J., Meeker T., Chan J.H., et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007, 37(12):3582-3586.
96. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. JAm Acad Dermatol 2011, 65(6):e179-e193.
97. Sigges J., Biazar C., Landmann A., et al. Therapeutic strategies evaluated by theEuropean Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 2013, 12(7):694-702.
98. Lauber K., Keppeler H., Munoz L.E., et al. Milk fat globule-EGF factor 8 mediates the enhancement of apoptotic cell clearance by glucocorticoids. Cell Death Differ 2013, 20(9):1230-1240.
99. Avgerinou G., Papafragkaki D.K., Nasiopoulou A., et al. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. JEur Acad Dermatol Venereol 2012, 26(6):762-767.
100. Pothinamthong P., Janjumratsang P. Acomparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. JMed Assoc Thai 2012, 95(7):933-940.
101. Kalia S., Dutz J.P. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007, 20(4):160-174.
102. Frances C., Cosnes A., Duhaut P., et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012, 148(4):479-484.
103. Chang A.Y., Piette E.W., Foering K.P., et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011, 147(11):1261-1267.
104. Kuznik A., Bencina M., Svajger U., et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. JImmunol 2011, 186(8):4794-4804.
105. Sacre K., Criswell L.A., McCune J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012, 14(3):R155.
106. Wozniacka A., Lesiak A., Boncela J., et al. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol 2008, 159(5):1124-1130.
107. Hansen C.B., Dahle K.W. Cutaneous lupus erythematosus. Dermatol Ther 2012, 25(2):99-111.
108. Moghadam-Kia S., Chilek K., Gaines E., et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 2009, 145(3):255-260.
109. Rentenaar R.J., Heydendael V.M., van Diepen F.N., et al. Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients. JClin Immunol 2004, 24(4):361-369.
110. Hornung T., Ko A., Tuting T., et al. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol 2012, 37(2):139-142.
111. Cortes-Hernandez J., Torres-Salido M., Castro-Marrero J., et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012, 166(3):616-623.
112. Cortes-Hernandez J., Avila G., Vilardell-Tarres M., et al. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012, 14(6):R265.
113. De Souza A., Strober B.E., Merola J.F., et al. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. JDrugs Dermatol 2012, 11(10):1224-1226.
114. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012, 83(12):1583-1590.
115. Ruzicka T., Sommerburg C., Goerz G., et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992, 127(5):513-518.
116. Newton R.C., Jorizzo J.L., Solomon A.R., et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986, 122(2):170-176.
117. Kuhn A., Patsinakidis N., Luger T. Alitretinoin for cutaneous lupus erythematosus. JAm Acad Dermatol 2012, 67(3):e123-e126.
118. Karadag A.S., Ertugrul D.T., Bilgili S.G., et al. Immunoregulatory effects of isotretinoin in patients with acne. Br J Dermatol 2012, 167(2):433-435.
119. Niu X., Cao W., Ma H., et al. Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris. JDermatol 2012, 39(11):916-921.
120. Green P.J., Pasternak S. Hypertrophic and ulcerated discoid lupus erythematosus. JCutan Med Surg 2012, 16(6):453-457.
121. Dahl C., Johansen C., Kragballe K., et al. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol 2013, 93(3):368-369.
122. De Souza A., Ali-Shaw T., Strober B.E., et al. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 2011, 147(8):896-898.
123. Kawasaki M., Fujishiro M., Yamaguchi A., et al. Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus 2011, 20(12):1231-1239.
124. Fridman J.S., Scherle P.A., Collins R., et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. JInvest Dermatol 2011, 131(9):1838-1844.
125. Ghoreschi K., Gadina M. Jackpot! new small molecules in autoimmune and inflammatory diseases. Exp Dermatol 2014, 23(1):7-11.
126. Martin D.A., Welcher A., Boedigheimer M., et al. AMG 811 (anti-IFN-gamma) treatment leads to a reduction in the whole blood IFN-signature and serum CXCL10 in subjects with systemic lupus erythematosus, 2013 systemic lupus erythematosus: results of two phase I studies. Arthritis Rheum 2013, 65(Suppl 10):S683. [abstract: 1609].
127. Hofmann S.C., Leandro M.J., Morris S.D., et al. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus-report of 17 cases and review of the literature. Lupus 2013, 22(9):932-939.
128. Merrill J.T., Ginzler E.M., Wallace D.J., et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012, 64(10):3364-3373.
129. Klein R., Moghadam-Kia S., LoMonico J., et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011, 147(2):203-208.
130. Makol A., Gibson L.E., Michet C.J. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. JClin Rheumatol 2012, 18(2):92-95.
131. Szepietowski J.C., Nilganuwong S., Wozniacka A., et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 2013, 65(10):2661-2671.
132. Merrill J.T., Wallace D.J., Petri M., et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011, 70(11):1905-1913.
133. Petri M., Wallace D.J., Spindler A., et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013, 65(4):1011-1021.
134. Zandman-Goddard G., Blank M., Shoenfeld Y. Intravenous immunoglobulins insystemic lupus erythematosus: from the bench to the bedside. Lupus 2009, 18(10):884-888.
135. Racz Z., Nagy E., Rosivall L., et al. Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus. Lupus 2010, 19(5):599-612.
136. Goodfield M., Davison K., Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). JDermatolog Treat 2004, 15(1):46-50.
137. Espirito Santo J., Gomes M.F., Gomes M.J., et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol 2010, 38(2-3):307-318.
138. Wiedeman A.E., Santer D.M., Yan W., et al. Contrasting mechanisms of interferon-alpha inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists. Arthritis Rheum 2013, 65(10):2713-2723.
139. Kessel A., Peri R., Haj T., et al. IVIg attenuates TLR-9 activation in B cells from SLE patients. JClin Immunol 2011, 31(1):30-38.